Adagene (ADAG) Stock Price

Adagene Price

NYSE·CLOSED
2.93
​
Market closed

Over the last 7 years Adagene grew revenue by 26.1% annually, reaching 7.67 M USD. For Adagene, the net margin of -229.6% is up versus -719.2% a few years ago. The consensus 12-month price target for Adagene is 10.00 USD, about 241.3% above where the stock trades today. Of 12 analysts, 10 rate the stock a buy — an overall Buy consensus.

Adagene stock price

Access this data via the Eulerpool API

Adagene business model & stock analysis

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Frequently asked questions about Adagene

Analysts currently set an average price target of 10.00 USD for the Adagene stock (median: 10.00 USD), implying +241.3 % versus the latest price. The consensus is based on 12 analyst ratings.

12 analysts currently rate the Adagene stock: 10 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Adagene to generate revenue of 5.16 M USD and earnings per share of -0.54 USD.

Converted at the current exchange rate, the Adagene share trades at 2.60 EUR (2.93 USD).

The expected revenue of Adagene is 5.16 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Adagene is -31.71 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Adagene is currently -5.47. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Adagene stock.

The price-to-sales ratio (P/S) of Adagene is currently 33.61. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Adagene stock.

The Eulerpool Quality Score for Adagene is 2/10.

The ISIN of Adagene is US0053291078. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Adagene is ADAG. The ticker symbol is used to trade Adagene shares on the stock exchange.

Fair ValueTerminal
2.70 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
59,928.92 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website adagene.com
Currency
USD
Initial public offering
Feb 9, 2021
ISIN
US0053291078
Cusip
005329107
Market capitalization
193.59 M USDMicro Cap
52-Week Range
PEG
-0.89
P/E ratio
P/Ee 2026
-5.47
P/Ee 2027
-4.08
P/Ee 2028
-3.97
P/Ee 2029
-2.90
P/Ee 2030
-3.24
P/Se
33.61
EV/EBIT
—
P/B Ratio
5.48
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-42.37 %
Last updated Oct 8, 2026, 12:54 AM

Adagene Peer Group

All fundamentals and in-depth analysis of Adagene

Our stock analysis for Adagene stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adagene. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.